Clinical Trial Search

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Goal Attainment of Preventive Health Behaviors as Measured by the Goal Attainment Scale — 40; 40; 57.5; 52.5 t-score

Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants

Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade

Primary: Bioelectrical Impedance Change — 47.52; 47.1; 41.27; 46.8 Percentage of Extra Cellular Fluid

Primary: Number of Subjects With at Least 30 Days of Daily Impedance Measurements — 47; 106 participants

Primary: All Cause Mortality — 163; 118 participants

Primary: Change in Left Ventricular Systolic Function. — .82; -1.90 percent LVEF — p=.14

Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001

Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL

Primary: Oxygen Uptake (VO2) Peak — 1778.1; 1228.2; 1393.7; 1763.6 ML/KG/Min

Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat

Primary: Patient Well Being, as Determined by a Visual Analog Scale — 4236; 4372.7; 4170.8; 4429.6 units on a scale

Primary: HF Hospitalizations and CV Death — 293; 372; 274; 363 Events — p=0.059

Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003

Primary: Number of Patients Free From Major Adverse Cardiac and Neurological Events (MACNE) at 6 Weeks. — 51 Participants

Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…

Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine

Primary: Exercise Capacity, as Determined by Peak Oxygen Uptake — -0.07; -0.12 ml/min/kg

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3.1; 3.2 events/participant

Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %

Primary: Carotid-femoral Pulse Wave Velocity — -0.3; 0.4 m/s — p=0.28

Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…

Primary: Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) — 36.1; 31.4; 63.1; 52.1 units on a scale — p=0.1641

Primary: Adherence to Medication — 2; 3 Participants

Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters

Primary: Functional Test — 115.91; 57.25 feet

Primary: Baseline Heart Rate Recovery — 32.5; 30.4 beats per minute

Primary: Number of Participants With HF-related Healthcare Resource Utilization (HCRU) — 64; 59 Participants